{"id":49518,"date":"2017-09-06T00:00:00","date_gmt":"2017-09-05T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/"},"modified":"2020-11-18T14:55:36","modified_gmt":"2020-11-18T13:55:36","slug":"aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/","title":{"rendered":"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial"},"content":{"rendered":"

The HTI immunogen brings together specific HIV antigenic regions. There is usually an enriched T-cell immune response towards these regions in those individuals who can control the virus without taking antiretroviral drugs.<\/p>\n

AELIX-002 is a phase I randomized, double-blind, placebo-controlled safety, tolerability, and immunogenicity study of the HTI vaccine.The enrollment of early diagnosed, early treated HIV-infected individuals in the trial should optimize the expansion of vaccine-associated immune responses. The trial is taking place at the University Hospital Germans Trias i Pujol<\/a>\u00a0in Badalona (Catalonia, Spain), and is performed by investigators from the\u00a0IrsiCaixa AIDS Research Institute<\/a>\u00a0and the\u00a0Fight AIDS Foundation<\/a>. Results are expected in 2018.<\/p>\n

\u201cThe AELIX-002 study builds upon our previous experience with therapeutic HIV vaccine trials. It will allow us to evaluate an exciting new HIV vaccine\u201d, said\u00a0Dr. Beatriz Mothe, principal investigator of the study at HUGTIP. \u201cThe vaccine has been designed with the goal of refocusing patients\u00b4 immune response to especially vulnerable sites of HIV so that they can control their HIV infection without further antiretroviral therapy.\u201d<\/p>\n

\u201cDeveloping a safe and effective therapeutic HIV vaccine that frees patients from the burden of antiretroviral therapy could be considered as the final frontier in HIV research\u201d said Dr. Ian McGowan, chief medical officer at AELIX Therapeutics. \u201cWe are very pleased to be able to partner with Dr. Mothe and her colleagues in evaluating the safety and immunogenicity of our HTI vaccine.\u201d
\n\u00a0<\/p>\n

\u25baFor further\u00a0information,\u00a0click\u00a0on\u00a0the following\u00a0<\/a>link\u00a0[+]<\/a><\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

Aelix Therapeutics<\/a>,\u00a0a drug development company based at the Barcelona Science Park and specialized in the discovery and development of immunotherapies for HIV infection , today announces that it has enrolled the first patient in its phase I clinical trial for the assessment of its proprietary HTI vaccine.<\/p>\n

\u00a0<\/p>\n","protected":false},"author":1,"featured_media":53213,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49518","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"\nAelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Aelix Therapeutics,\u00a0a drug development company based at the Barcelona Science Park and specialized in the discovery and development of immunotherapies for HIV infection , today announces that it has enrolled the first patient in its phase I clinical trial for the assessment of its proprietary HTI vaccine. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-05T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T13:55:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16057066775fb523b517f00.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"412\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial\",\"datePublished\":\"2017-09-05T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/\"},\"wordCount\":256,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16057066775fb523b517f00.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/\",\"name\":\"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16057066775fb523b517f00.jpeg\",\"datePublished\":\"2017-09-05T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16057066775fb523b517f00.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16057066775fb523b517f00.jpeg\",\"width\":800,\"height\":412},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial - Parc Cient\u00edfic de Barcelona","og_description":"Aelix Therapeutics,\u00a0a drug development company based at the Barcelona Science Park and specialized in the discovery and development of immunotherapies for HIV infection , today announces that it has enrolled the first patient in its phase I clinical trial for the assessment of its proprietary HTI vaccine. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2017-09-05T23:00:00+00:00","article_modified_time":"2020-11-18T13:55:36+00:00","og_image":[{"width":800,"height":412,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16057066775fb523b517f00.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial","datePublished":"2017-09-05T23:00:00+00:00","dateModified":"2020-11-18T13:55:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/"},"wordCount":256,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16057066775fb523b517f00.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/","url":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/","name":"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16057066775fb523b517f00.jpeg","datePublished":"2017-09-05T23:00:00+00:00","dateModified":"2020-11-18T13:55:36+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16057066775fb523b517f00.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16057066775fb523b517f00.jpeg","width":800,"height":412},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Aelix Therapeutics enrolls first patient in company\u2019s initial therapeutic HIV vaccine clinical trial"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=49518"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49518\/revisions"}],"predecessor-version":[{"id":53212,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49518\/revisions\/53212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/53213"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=49518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=49518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=49518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}